Year: All Releases2018201720162015201420132012 November 27, 2018 Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer PDF Version November 13, 2018 Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates PDF Version November 12, 2018 Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer PDF Version November 12, 2018 Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018 PDF Version November 8, 2018 Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference PDF Version November 6, 2018 Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates PDF Version September 26, 2018 Mersana Therapeutics to Present at Upcoming Investor Conferences PDF Version September 25, 2018 Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer PDF Version September 17, 2018 Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522 PDF Version August 30, 2018 Mersana Therapeutics to Present at Upcoming Investor Conferences PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
